Taysha Gene Therapies, Inc. Operating Income
Taysha Gene Therapies, Inc. (TSHA) reported Operating Income of -$47.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Taysha Gene Therapies, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$47.35M.
- Taysha Gene Therapies, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$43.49M.
- Taysha Gene Therapies, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$28.30M.
- Taysha Gene Therapies, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$34.02M.
- Taysha Gene Therapies, Inc. operating income (loss) for fiscal 2025 was -$110.50M.
- Taysha Gene Therapies, Inc. operating income (loss) for fiscal 2024 was -$91.46M.
- Taysha Gene Therapies, Inc. operating income (loss) for fiscal 2023 was -$72.44M.
- Taysha Gene Therapies, Inc. operating income (loss) for fiscal 2022 was -$162.45M.
| Period end | Operating Income (Loss) 0 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$47.35M 10-Q · filed 2026-08-11 | -$90.83M 10-Q · filed 2026-08-11 | -$119.14M derived: sum of 3 quarters · filed 2026-08-11 | -$153.16M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$43.49M 10-Q · filed 2026-05-06 | -$71.79M derived: sum of 2 quarters · filed 2026-05-06 | -$105.81M derived: sum of 3 quarters · filed 2026-05-06 | -$132.56M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$28.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$62.32M derived: sum of 2 quarters · filed 2026-03-19 | -$89.08M derived: sum of 3 quarters · filed 2026-08-11 | -$110.50M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$34.02M 10-Q · filed 2025-11-04 | -$60.78M derived: sum of 2 quarters · filed 2026-08-11 | -$82.20M 10-Q · filed 2025-11-04 | -$102.13M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$26.75M 10-Q · filed 2026-08-11 | -$48.17M 10-Q · filed 2026-08-11 | -$68.11M derived: sum of 3 quarters · filed 2026-08-11 | -$94.00M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$21.42M 10-Q · filed 2026-05-06 | -$41.35M derived: sum of 2 quarters · filed 2026-05-06 | -$67.25M derived: sum of 3 quarters · filed 2026-05-06 | -$88.55M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$19.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$45.83M derived: sum of 2 quarters · filed 2026-03-19 | -$67.13M derived: sum of 3 quarters · filed 2026-03-19 | -$91.46M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$25.90M 10-Q · filed 2025-11-04 | -$47.20M derived: sum of 2 quarters · filed 2025-11-04 | -$71.53M 10-Q · filed 2025-11-04 | -$87.77M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | -$21.30M 10-Q · filed 2025-08-12 | -$45.63M 10-Q · filed 2025-08-12 | -$61.88M derived: sum of 3 quarters · filed 2025-08-12 | -$78.13M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$24.33M 10-Q · filed 2025-05-15 | -$40.58M derived: sum of 2 quarters · filed 2025-05-15 | -$56.83M derived: sum of 3 quarters · filed 2025-05-15 | -$80.21M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$16.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$32.50M derived: sum of 2 quarters · filed 2025-02-26 | -$55.88M derived: sum of 3 quarters · filed 2025-02-26 | -$72.44M 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | -$16.25M 10-Q · filed 2024-11-13 | -$39.63M derived: sum of 2 quarters · filed 2024-11-13 | -$56.19M 10-Q · filed 2024-11-13 | -$110.16M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$23.38M 10-Q · filed 2024-08-12 | -$39.94M 10-Q · filed 2024-08-12 | -$93.91M derived: sum of 3 quarters · filed 2024-08-12 | -$119.37M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$16.56M 10-Q · filed 2024-05-14 | -$70.53M derived: sum of 2 quarters · filed 2024-05-14 | -$95.98M derived: sum of 3 quarters · filed 2024-05-14 | -$129.35M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$53.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$79.42M derived: sum of 2 quarters · filed 2024-03-19 | -$112.80M derived: sum of 3 quarters · filed 2024-03-19 | -$162.45M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | -$25.46M 10-Q · filed 2023-11-14 | -$25.07M 10-Q · filed 2022-11-08 | -$58.83M derived: sum of 2 quarters · filed 2023-11-14 | -$108.48M 10-Q · filed 2023-11-14 | -$107.33M 10-Q · filed 2022-11-08 | -$158.21M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$33.37M 10-Q · filed 2023-08-14 | -$32.98M 10-Q · filed 2022-08-11 | -$83.02M 10-Q · filed 2023-08-14 | -$82.25M 10-Q · filed 2022-08-11 | -$132.75M derived: sum of 3 quarters · filed 2023-08-14 | -$183.43M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$49.65M 10-Q · filed 2023-05-11 | -$49.27M 10-Q · filed 2022-05-16 | -$99.38M derived: sum of 2 quarters · filed 2023-05-11 | -$150.06M derived: sum of 3 quarters · filed 2023-05-11 | -$190.83M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$49.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$100.41M derived: sum of 2 quarters · filed 2023-03-28 | -$141.18M derived: sum of 3 quarters · filed 2023-03-28 | -$173.27M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | -$50.68M 10-Q · filed 2022-11-08 | -$91.45M derived: sum of 2 quarters · filed 2022-11-08 | -$123.54M 10-Q · filed 2022-11-08 | -$141.91M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$40.77M 10-Q · filed 2022-08-11 | -$72.86M 10-Q · filed 2022-08-11 | -$91.23M derived: sum of 3 quarters · filed 2022-08-11 | -$106.27M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$32.09M 10-Q · filed 2022-05-16 | -$50.46M derived: sum of 2 quarters · filed 2022-05-16 | -$65.50M derived: sum of 3 quarters · filed 2022-05-16 | -$69.51M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$33.41M derived: sum of 2 quarters · filed 2022-03-31 | -$37.42M derived: sum of 3 quarters · filed 2022-03-31 | -$43.00M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$15.04M 10-Q · filed 2021-11-10 | -$19.05M derived: sum of 2 quarters · filed 2021-11-10 | -$24.64M 10-Q · filed 2021-11-10 | -$25.75M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$4.01M 10-Q · filed 2021-08-16 | -$9.59M 10-Q · filed 2021-08-16 | -$10.71M derived: sum of 3 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | -$5.58M 10-Q · filed 2021-05-11 | -$6.70M derived: sum of 2 quarters · filed 2021-05-11 | ||||||
| 2019-12-31 | -$1.11M 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | -$31.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |